At Houston Methodist, the Postdoctoral Fellow position is responsible for performing basic research duties under the supervision/direction of a Physician and/or Principal Investigator (PI). This position may work in a laboratory setting or may consist of computer work that supports the department's research mission. Preferred candidates to have experience in cancer molecular biology, cancer mouse models, cancer pharmacology and/or immuno-oncology and a sincere interest in translational research for the benefit of cancer patients.
The Rostomily-Mikheev Lab at the Houston Methodist Research Institute is seeking a post-doctoral fellow to establish the role of novel dual NR4A1 and NR4A2 nuclear orphan receptor inhibitors in glioblastoma (GBM). NR4A1/2 drives crosstalk between immune suppression and EMT and their inhibition is hypothesized to overcome resistance to immune checkpoint blockade and standard TMZ/XRT therapies by concurrently reprogramming the mesenchymal and immune suppressive tumor microenvironment. The candidate will be involved in quantifying the effects of NR4A1/2 inhibition on reprogramming the GBM TME in syngeneic models using multiple approaches including scRNAseq, spatial IHC and transcriptomics and bioinformatic modeling to measure TME changes. The role of NR4A1/2 regulated targets, TWIST1 and PD-L1, in TME modulation and treatment responses will be defined through gain and loss of function studies. These studies are expected to support clinical development of the NR4A1/2 drugs as standalone or adjuvant therapies to potentiate current standard of care and/or immune checkpoint treatment in GBM.
The position is open and available for starting immediately. The project is funded through a recently awarded R01 “Pharmacologic targeting of NR4A1 and NR4A2 to activate glioblastoma treatment response” (1R01NS129720) in collaboration with Dr Steven Safe at Texas A&M who developed the drugs and has expertise in NR4A1/2 in cancer. Competitive candidates are expected to have experience in cancer molecular biology, cancer mouse models, cancer pharmacology and/or immuno-oncology and a sincere interest in translational research for the benefit of cancer patients.
PATIENT AGE GROUP(S) AND POPULATION(S) SERVED
Refer to departmental "Scope of Service" and "Provision of Care" plans, as applicable, for description of primary age groups and populations served by this job for the respective HM entity.
HOUSTON METHODIST EXPERIENCE EXPECTATIONS
PEOPLE ESSENTIAL FUNCTIONS
SERVICE ESSENTIAL FUNCTIONS
QUALITY/SAFETY ESSENTIAL FUNCTIONS
FINANCE ESSENTIAL FUNCTIONS
GROWTH/INNOVATION ESSENTIAL FUNCTIONS
This job description is not intended to be all-inclusive; the employee will also perform other reasonably related business/job duties as assigned. Houston Methodist reserves the right to revise job duties and responsibilities as the need arises.
EDUCATION
WORK EXPERIENCE
LICENSES AND CERTIFICATIONS - REQUIRED
KNOWLEDGE, SKILLS, AND ABILITIES
SUPPLEMENTAL REQUIREMENTS
WORK ATTIRE
ON-CALL*
*Note that employees may be required to be on-call during emergencies (ie. DIsaster, Severe Weather Events, etc) regardless of selection below.
TRAVEL**
**Travel specifications may vary by department**
Houston Methodist Research Institute was formed in 2004 to rapidly and efficiently translate discoveries made in the laboratory and the clinic into new diagnostics, therapies, and treatments. The research institute was created to provide the infrastructure and support for these endeavors, and to house the technology and resources needed to make innovative breakthroughs in important areas of human disease. A 540,000 square foot building dedicated to research, the research institute houses over 1,500 staff and trainees, 284 principal investigators and has more than 570 ongoing clinical trials.
Software Powered by iCIMS
www.icims.com